Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
01 1Chunghwa Chemical Synthesis & Biotech. Ltd
02 1HAS Healthcare Advanced Synthesis SA
03 1HETERO LABS LIMITED
04 1LAURUS LABS LIMITED
05 1Lianyungang Runzhong Pharmaceutical Co., Ltd.
06 1MSN Laboratories Private Limited
07 2Patheon Manufacturing Services LLC
08 1Sionc Pharmaceutical Private Limited
09 1TAPI Croatia Industries Ltd.
01 2CARFILZOMIB
02 8Carfilzomib
01 1China
02 4India
03 1Switzerland
04 1Taiwan
05 2U.S.A
06 1Blank
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
NDC Package Code : 52076-6251
Start Marketing Date : 2012-10-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 67262-0010
Start Marketing Date : 2012-07-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER, FOR SOLUTION (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 68554-0163
Start Marketing Date : 2019-09-09
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 42385-731
Start Marketing Date : 2016-03-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 61662-0022
Start Marketing Date : 2023-11-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0037
Start Marketing Date : 2015-08-04
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 63552-009
Start Marketing Date : 2012-07-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (60mg/30mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 63552-035
Start Marketing Date : 2012-07-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (30mg/15mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 76055-0035
Start Marketing Date : 2018-05-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 11722-059
Start Marketing Date : 2015-07-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100kg/100kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
A Carfilzomib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Carfilzomib, including repackagers and relabelers. The FDA regulates Carfilzomib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Carfilzomib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Carfilzomib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Carfilzomib supplier is an individual or a company that provides Carfilzomib active pharmaceutical ingredient (API) or Carfilzomib finished formulations upon request. The Carfilzomib suppliers may include Carfilzomib API manufacturers, exporters, distributors and traders.
click here to find a list of Carfilzomib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Carfilzomib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Carfilzomib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Carfilzomib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Carfilzomib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Carfilzomib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Carfilzomib suppliers with NDC on PharmaCompass.
We have 8 companies offering Carfilzomib
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
